Previous 10 | Next 10 |
AxoGen has reported two consecutive quarters of double-digit growth despite lower trauma presentations during the pandemic and restrictions on marketing/training efforts. Clinical data continue to support the company's key products, with patients experience reduced pain/improved sensa...
Axogen (AXGN) promotes CFO Peter J. Mariani to executive vice president, in addition to his current finance chief role.Mariani has served as Axogen’s chief financial officer since 2016"This expanded role recognizes Pete’s significant and ongoing contributions to Axogen ...
ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer. ...
ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December...
ALACHUA, Fla., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of pilot phase analysis for its REPOSE clinical study. Ana...
ALACHUA, Fla., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report fourth quarter and full-year 2020 financial results on ...
Axogen ([[AXGN]] +1.7%) reported preliminary unaudited 4Q20 revenue of $32.4M (+15% Y/Y) vs. $29.52M consensus and FY20 revenue of $112.2M (+5% Y/Y) vs. $109.34M consensus.Axogen increased active accounts in Q4 to 893, a 12% increase from 797 in Q4 a year ago.Company’s top 10% of activ...
ALACHUA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2020 revenue. Preliminary Unaudited...
ALACHUA, Fla., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2021 meetings of the American Associati...
ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today their sponsorship of Donate Life at the annual Tournament of Roses ®...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...